Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus

[1]  Y. Natkunam,et al.  Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis , 2020, International journal of molecular sciences.

[2]  I. Chaban,et al.  Distinct Differentiation Characteristics of Endothelium Determine Its Ability to Form Pseudo-Embryos in Tomato Ovules , 2019, International journal of molecular sciences.

[3]  M. Infantino,et al.  European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view , 2019, Annals of the Rheumatic Diseases.

[4]  D. Gladman,et al.  2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus , 2019, Arthritis & rheumatology.

[5]  D. Gladman,et al.  2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus , 2019, Annals of the rheumatic diseases.

[6]  H. Matsuoka,et al.  Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin , 2019, Annals of Hematology.

[7]  R. Suzuki,et al.  JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK/T-cell lymphoma, nasal type (ENKL) , 2019, International Journal of Hematology.

[8]  Le-Bin Song,et al.  The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis , 2018, Arthritis Research & Therapy.

[9]  A. Polliack,et al.  Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology. , 2018, Leukemia research.

[10]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[11]  S. Bernatsky,et al.  A review on SLE and malignancy. , 2017, Best practice & research. Clinical rheumatology.

[12]  H. Sasano,et al.  Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi Prefecture , 2017, Leukemia & lymphoma.

[13]  S. Bernatsky,et al.  Malignancies in systemic lupus erythematosus: a 2015 update , 2015, Current opinion in rheumatology.

[14]  D. Heo,et al.  Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities , 2015, Leukemia & lymphoma.

[15]  G. Houen,et al.  Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients , 2015, Scandinavian journal of rheumatology.

[16]  Sang‐wook Lee,et al.  Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study , 2014, Annals of Hematology.

[17]  A. Avenell,et al.  Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus , 2014, Arthritis Research & Therapy.

[18]  D. Gladman,et al.  Lymphoma risk in systemic lupus: effects of disease activity versus treatment , 2012, Annals of the rheumatic diseases.

[19]  D. Gladman,et al.  Cancer risk in systemic lupus: an updated international multi-centre cohort study. , 2013, Journal of autoimmunity.

[20]  T. Yoshino,et al.  Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Sang‐wook Lee,et al.  Clinical features and prognostic model for extranasal NK/T‐cell lymphoma , 2012, European journal of haematology.

[22]  R. Suzuki.  Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia , 2010, International journal of hematology.

[23]  M. Mok,et al.  Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus , 2010, Lupus.

[24]  K. Ohshima,et al.  Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Weisenburger,et al.  Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. , 2009, Blood.

[26]  K. Costenbader,et al.  Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin’s lymphoma (NHL) , 2007, Clinical Rheumatology.

[27]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Journal of the American Society of Nephrology : JASN.

[28]  Kong-Chao Chang,et al.  EBER-1 positive diffuse large cell lymphoma presenting as lupus nephritis , 2003, Lupus.